产品名称 |
HuH-28人胆管癌细胞 |
货号 |
ZQ1030 |
产品介绍 |
HuH-28是一种人肝脏胆管癌细胞系,它在胆管癌(Cholangiocarcinoma)的研究中被广泛使用。胆管癌是一种发生在胆管上皮细胞的恶性肿瘤,通常分为肝内胆管癌和肝外胆管癌。该细胞系可以用于CXCL7促进胆管癌细胞的增殖和侵袭的研究。通过RT-PCR分析、免疫印迹试验、酶联免疫吸附试验(ELISA)、MTT试验和Transwell试验等方法,可以检测HuH-28人胆管癌细胞系细胞增殖和侵袭性。
HuH-28细胞系在胆管癌研究中的应用中不限于以下几个方面:药物筛选、肿瘤发生机制的研究、抗肿瘤药物的筛选和评价、肿瘤免疫治疗的研究、基因表达和信号通路研究、肿瘤干细胞特性研究、肝胆系统肿瘤药物基因组学研究、胆管癌胞外囊泡circRNA研究等。这些应用场景展示了HuH-28细胞系在胆管癌研究中的多样性和重要性,为胆管癌的基础研究和临床治疗提供了重要的实验模型和研究工具。 |
种属 |
人 |
性别/年龄 |
女/37岁 |
组织 |
肝 |
疾病 |
肝癌 |
细胞类型 |
肿瘤细胞 |
形态学 |
上皮的 |
生长方式 |
贴壁 |
倍增时间 |
~80 hours (PubMed=2852388); ~1 week (Note=Lot 09082006), ~88 hours (Note=Lot 01062011), 55-128 hours (Note=Lot 07222016), 5 days (Note=Lot 10022018) (JCRB=JCRB0426) |
培养基和添加剂 |
RPMI-1640(品牌:中乔新舟 货号:ZQ-200)+10%胎牛血清(中乔新舟 货号:ZQ500-A)+1%双抗(中乔新舟 货号:CSP006) |
推荐完全培养基货号 |
|
培养条件 |
95%空气,5%二氧化碳;37℃ |
STR位点信息 |
Amelogenin :X CSF1PO :9,12 D2S1338 :19 D3S1358 :15,16 D5S818 :9,12 D7S820 :10 (RCB=RCB1943) :10,11 (JCRB=JCRB0426; PubMed=25877200; TKG=TKG 0438) D8S1179 :11 D13S317 :9,12 D16S539: 9 D18S51: 15 D19S433: 13,14.2 D21S11: 30,33.2 FGA :23 Penta D :9,10 Penta E: 13,22 TH01: 9 TPOX :8 vWA :17 |
生物安全等级 |
BSL-1 |
保藏机构 |
JCRB; JCRB0426;RCB; RCB1943 |
供应限制 |
仅供科研使用 |
货号 |
ZQ1030 |
发货规格 |
活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一 |
发货形式 |
活细胞:常温运输;冻存管:干冰运输 |
储存温度 |
活细胞:培养箱;冻存管:液氮罐 |
产地 |
中国 |
供应限制 |
仅供科研使用 |
PubMed=2852388; DOI=10.1007/BF01851205
Kusaka Y., Tokiwa T., Sato J.
Establishment and characterization of a cell line from a human cholangiocellular carcinoma.
Res. Exp. Med. (Berl.) 188:367-375(1988)
PubMed=2856443
Kusaka Y., Muraoka A., Tokiwa T., Sato J.
Establishment and characterization of a human cholangiocellular carcinoma cell line.
Hum. Cell 1:92-94(1988)
PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)
PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=21451941; DOI=10.1007/s00534-011-0376-7
Sato J., Kimura T., Saito T., Anazawa T., Kenjo A., Sato Y., Tsuchiya T., Gotoh M.
Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
J. Hepatobiliary Pancreat. Sci. 18:700-711(2011)
PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)
PubMed=26956050; DOI=10.18632/oncotarget.7914
Ding X.-W., Chaiteerakij R., Moser C.D., Shaleh H.M., Boakye J., Chen G., Ndzengue A., Li Y., Zhou Y.-L., Huang S.-B., Sinicrope F.A., Zou X.-P., Thomas M.B., Smith C.D., Roberts L.R.
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Oncotarget 7:20080-20092(2016)
PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442
Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C., Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K., Greninger P., McDermott U., Garnett M.J., Jenkins R.L., Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y., Goyal L., Ferrone C.R., Zhu A.X., Joung J.K., Shokat K.M., Benes C.H., El-Bardeesy N.
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.
Cancer Discov. 6:727-739(2016)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=31077409; DOI=10.1002/hep.30704
Sittithumcharee G., Suppramote O., Vaeteewoottacharn K., Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M., Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K., Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P., Pairojkul C., Wongkham S., Sampattavanich S., Okada S., Jirawatnotai S.
Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity.
Hepatology 70:1614-1630(2019)